Trial reportTherapeutic drug monitoring2011
Preliminary buprenorphine sublingual tablet pharmacokinetic data in plasma, oral fluid, and sweat during treatment of opioid-dependent pregnant women.
Trial report in Therapeutic drug monitoring, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Pregnancy-Associated Changes in Pharmacokinetics: A Systematic Review.PLoS medicine · 2016Pooled it
- Consensus Panel Recommendations for the Pharmacological Management of Breastfeeding Women with Postpartum Depression.International journal of environmental research and public health · 2024Review
- Interaction between buprenorphine and norbuprenorphine in neonatal opioid withdrawal syndrome.Drug and alcohol dependence · 2023Article
- Clearance of buprenorphine during pregnancy and neonatal outcomes.Archives of women's mental health · 2021Observational
- Pharmacokinetics of buprenorphine in pregnant sheep after intravenous injection.Pharmacology research & perspectives · 2021Review
- Buprenorphine dosing for the treatment of opioid use disorder through pregnancy and postpartum.Current treatment options in psychiatry · 2020Article
- Pregnancy Alters CYP- and UGT-Mediated Metabolism of Buprenorphine.Therapeutic drug monitoring · 2020Article
- Opioid use disorder in pregnancy.The mental health clinician · 2019Article
- In Utero Exposure to Norbuprenorphine, a Major Metabolite of Buprenorphine, Induces Fetal Opioid Dependence and Leads to Neonatal Opioid Withdrawal Syndrome.The Journal of pharmacology and experimental therapeutics · 2019Article
- Opioid Use in Pregnant Women and Neonatal Abstinence Syndrome-A Review of the Literature.Toxics · 2019Review
- Pregnancy Increases Norbuprenorphine Clearance in Mice by Induction of Hepatic Glucuronidation.Drug metabolism and disposition: the biological fate of chemicals · 2018Article
- An evidence-based recommendation to increase the dosing frequency of buprenorphine during pregnancy.American journal of obstetrics and gynecology · 2017Article
- P-gp/ABCB1 exerts differential impacts on brain and fetal exposure to norbuprenorphine.Pharmacological research · 2017Article
- Dose-adjusted plasma concentrations of sublingual buprenorphine are lower during than after pregnancy.American journal of obstetrics and gynecology · 2017Article
- Obstetric Pharmacokinetic Dosing Studies are Urgently Needed.Frontiers in pediatrics · 2014Review
- Buprenorphine use in pregnant opioid users: a critical review.CNS drugs · 2013Review
- Transdermal buprenorphine-interesting observations on the metabolite norbuprenorphine levels in elderly subjects.European journal of clinical pharmacology · 2013Article
- A Pharmacologic Evaluation of Buprenorphine in Pregnancy and the Postpartum Period.Journal of addiction medicineArticle
- Buprenorphine Salivary Gland Accumulation Sustaining High Oral Fluid Exposure and Increasing the Risk of Streptococcus mutans Biofilm Formation.Journal of addiction medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundBuprenorphine is currently under investigation as a pharmacotherapy to treat pregnant women for opioid dependence. This research evaluates buprenorphine (BUP), norbuprenophine (NBUP), buprenorphine-glucuronide (BUP-Gluc), and norbuprenorphine-glucuronide (NBUP-Gluc) pharmacokinetics after high-dose (14-20 mg) BUP sublingual tablet administration in three opioid-dependent pregnant women.
methodsOral fluid and sweat specimens were collected in addition to plasma specimens for 24 hours during gestation weeks 28 or 29 and 34, and 2 months after delivery. Time to maximum concentration was not affected by pregnancy; however, BUP and NBUP maximum concentration and area under the curve at 0 to 24 hours tended to be lower during pregnancy compared with postpartum levels.
resultsStatistically significant but weak positive correlations were found for BUP plasma and OF concentrations and BUP/NBUP ratios in plasma and oral fluid. Statistically significant negative correlations were observed for times of specimen collection and BUP and NBUP oral fluid/plasma ratios. BUP-Gluc and NBUP-Gluc were detected in only 5% of oral fluid specimens. In sweat, BUP and NBUP were detected in only four of 25 (12 or 24 hours) specimens in low concentrations (less than 2.4 ng/patch).
conclusionThese preliminary data describe BUP and metabolite pharmacokinetics in pregnant women and suggest that, like methadone, upward dose adjustments may be needed with advancing gestation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.